Wed, Jul 30, 2014, 4:42 PM EDT - U.S. Markets closed


% | $
Click the to save as a favorite.

Immune Pharmaceuticals, Inc. Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • larshansson18 larshansson18 Feb 16, 2009 6:13 PM Flag

    OPEN LETTER to EpiCept Managament

    Is your point that J T should dilute the patents instead of doing the last PP?

    Every Big Ph cashflow CO lessens the expenditures from basic research these days. But you recommend us to not follow that road? Are you familliar with the actual development in the industry?

    What if you make a calculation of the effect of the last dilution versus the maginal effect on profit from the cut of the San Diego department?

    I invested in Epicept after the European approval. I look upon the situation like this:

    The worst thing to do in a negotiation is to be depending on time, - or crying sharholders that can not afford to wait. That is a very challanging but nice characteristic: to afford waiting. You might make fun of that, but I have to much money in this for your amateurism. So spear me that.

    NP-1 is moving right, the upcoming fas III versus the 3 different blood cancers are , one by one coming to place, Myriad is soon reporting on Azixa and our VDA, Eps 2407, will also be in the news soon.

    Sell or stay in.

    In Greece it is possible to hire ladies crying...On the net everythings goes down to zero costs, I imagine.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
4.08-0.02(-0.49%)3:59 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.